Leydig Cells, also known as interstitial cells, are crucial components of the male reproductive system, predominantly found in the interstitial tissue of the testes. These specialized endocrine cells play a central role in testosterone production, a key male sex hormone essential for the development and maintenance of male reproductive tissues and secondary sexual characteristics. Leydig cells respond to luteinizing hormone (LH) signals from the pituitary gland, which stimulate them to synthesize and release testosterone. This hormone is pivotal for the maturation of sperm, the development of male secondary sexual characteristics like facial hair and deepening of the voice, and overall reproductive health. Leydig cells exhibit remarkable plasticity, adapting their function to various physiological conditions. Dysregulation of Leydig cell function can result in testosterone imbalances, impacting fertility, libido, and overall male reproductive health. Understanding the biology of Leydig cells is crucial for unraveling the complexities of male reproductive physiology, and their study holds implications for the diagnosis and treatment of conditions related to testosterone deficiency or excess. Ongoing research in Leydig cell biology aims to explore potential therapeutic interventions for disorders affecting male reproductive health.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy